login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
DIANTHUS THERAPEUTICS INC (DNTH) Stock News
NASDAQ:DNTH -
US2528281080
-
Common Stock
23.735
USD
-1.07 (-4.33%)
Last: 8/29/2025, 12:23:04 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
DNTH Latest News, Press Relases and Analysis
All
Press Releases
16 days ago - By: Toi Management, LLC
- Mentions:
TOI
The Oncology Institute Announces Changes to Board of Directors
22 days ago - By: Zacks Investment Research
- Mentions:
CVAC
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
22 days ago - By: The Motley Fool
Dianthus (DNTH) Q2 Loss Widens 80%
4 months ago - By: Benzinga
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
8 months ago - By: Benzinga
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics
22 days ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
22 days ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
22 days ago - By: Zacks Investment Research
- Mentions:
INO
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
23 days ago - By: Zacks Investment Research
- Mentions:
SEER
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
2 months ago - By: Yahoo Finance
Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside
3 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
3 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
3 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
3 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
4 months ago - By: Zacks Investment Research
- Mentions:
VTGN
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
4 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
4 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
4 months ago - By: Zacks Investment Research
- Mentions:
EBS
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
4 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
4 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
4 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
4 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
6 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
6 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
6 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
6 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
6 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
6 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
7 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
7 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
8 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
8 months ago - By: Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Please enable JavaScript to continue using this application.